Monday, March 30, 2015

Adamis Pharmaceuticals (ADMP) Has Crashed (Buying Opportunity?)

Adamis Pharmaceuticals (ADMP) issued a press release this morning (02015.03.30) having the following headline: Adamis Pharmaceuticals Receives Complete Response Letter From FDA for Its Epinephrine Pre-Filled Syringe NDA.

From the press release.

A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form.

ADMP closed yesterday (02015.03.29) $5.39. It opened today at $4.19 and closed at $3.83, down almost 29% (intra-day low was 3.56). Volume was 1.86 million vs. 0.19 million. 52-week range: $2.62 - $7.26.

Since the news was released some shareholder class action lawsuits are been initiated.

No comments:

Post a Comment